Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

Shigeaki Suzuki, Tetsuya Nishimoto, Mitsutomo Kohno, Kimiaki Utsugisawa, Yuriko Nagane, Masataka Kuwana, Norihiro Suzuki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalJournal of Neuroimmunology
Volume258
Issue number1-2
DOIs
Publication statusPublished - 2013 Apr 3

Keywords

  • Anti-Kv1.4 antibody
  • Myasthenia gravis
  • Prognosis
  • Thymoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis'. Together they form a unique fingerprint.

  • Cite this